Publication | Open Access

Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation

Cancer ImmunosurveillanceAutoimmune DiseaseMedicineImmunologyPd-1/pd-l1 Checkpoint InhibitorsImmune SurveillanceAutoimmunityClinical OutcomesImmune Checkpoint InhibitorCancer TreatmentNsclc PatientsImmunotherapyOncology